Journal of Hepatocellular Carcinoma

Combination of Immune Checkpoint Inhibitors and Locoregional Therapy of Hepatocellular Carcinoma: Hype or Hope

In recent years, immune checkpoint inhibitor and its combinations have revolutionized the management of patients with advanced hepatocellular carcinoma. The combinations of atezolizumab plus bevacizumab and durvalumab plus tremelimumab demonstrated the overall survival benefits over sorafenib in the first line setting, while pembrolizumab was superior to placebo in patients who were refractory to sorafenib as second-line therapy. Current ongoing studies are focused on combining immunotherapy with locoregional therapy (LRT) to augment the anti-tumor immune response. This Article Collection summarizes the recent advances and unanswered questions in the field.